# RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

> **NCT04827862** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 6 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04827862
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827862, "RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04827862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*